| 1254179-01-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• CAS: 1254179-01-5
• 化学式: C₁₉H₂₂N₆O₃
• 分子量: 382.422
• InChiKey: FICWXAPOGIEJJR-JOCQHMNTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.62
• 重原子数：
  28.0
• 可旋转键数：
  3.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  129.04
• 氢给体数：
  2.0
• 氢受体数：
  9.0

反应信息

• 作为产物：
  描述：

  、 alkaline earth salt of/the/ methylsulfuric acid 在 bis-triphenylphosphine-palladium(II) chloride 、 potassium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors

  摘要：

  Pteridinones were designed based on a non-selective kinase template. Because of the uniqueness of the PI3K and mTOR binding pockets, a methyl group was introduced to C-4 position of the peteridinone core to give compounds with excellent selectivity for PI3K and mTOR. This series of compounds were further optimized to improve their potency against PI3K alpha and mTOR. Finally, orally active compounds with improved solubility and robust in vivo efficacy in tumor growth inhibition were identified as well. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.045

文献信息

• TREATMENT OF CANCERS HAVING K-RAS MUTATIONS
  申请人：Curis, Inc.

  公开号：US20130102595A1

  公开（公告）日：2013-04-25

  The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

  本发明提供了一种治疗与K-ras突变相关的癌症的方法，适用于需要该方法的受试者。该方法包括以下步骤：（1）识别患有与K-ras突变相关的癌症的受试者；和（2）向受试者施用（i）PI3激酶抑制剂和（ii）HDAC抑制剂，其中PI3激酶抑制剂和HDAC抑制剂以联合治疗有效的剂量进行施用。
• [EN] TREATMENT OF CANCERS HAVING K-RAS MUTATIONS<br/>[FR] TRAITEMENT DE CANCERS PRÉSENTANT DES MUTATIONS K-RAS
  申请人：CURIS INC

  公开号：WO2011130628A1

  公开（公告）日：2011-10-20

  The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

  本发明提供了一种治疗与K-ras突变相关的癌症的方法，适用于需要该方法的受试者。该方法包括以下步骤：(1) 鉴定患有与K-ras突变相关的癌症的受试者；和 (2) 给予该受试者 (i) PI3激酶抑制剂和 (ii) HDAC抑制剂，其中PI3激酶抑制剂和HDAC抑制剂以治疗有效的剂量一起给予。
• 4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors
  作者：Kevin K.-C. Liu、Shubha Bagrodia、Simon Bailey、Hengmiao Cheng、Hui Chen、Lisa Gao、Samantha Greasley、Jacqui E. Hoffman、Qiyue Hu、Ted O. Johnson、Dan Knighton、Zhengyu Liu、Matthew A. Marx、Mitchell D. Nambu、Sacha Ninkovic、Bernadette Pascual、Kristina Rafidi、Caroline M.-L. Rodgers、Graham L. Smith、Shaoxian Sun、Haitao Wang、Anle Yang、Jing Yuan、Aihua Zou

  DOI：10.1016/j.bmcl.2010.08.045

  日期：2010.10

  Pteridinones were designed based on a non-selective kinase template. Because of the uniqueness of the PI3K and mTOR binding pockets, a methyl group was introduced to C-4 position of the peteridinone core to give compounds with excellent selectivity for PI3K and mTOR. This series of compounds were further optimized to improve their potency against PI3K alpha and mTOR. Finally, orally active compounds with improved solubility and robust in vivo efficacy in tumor growth inhibition were identified as well. (C) 2010 Elsevier Ltd. All rights reserved.